"Indazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D007191
|
| MeSH Number(s) |
D03.383.129.539.487 D03.633.100.449
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indazoles".
Below are MeSH descriptors whose meaning is more specific than "Indazoles".
This graph shows the total number of publications written about "Indazoles" by people in this website by year, and whether "Indazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 5 | 6 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 3 | 3 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indazoles" by people in Profiles.
-
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 02; 220:115308.
-
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. J Clin Oncol. 2023 11 01; 41(31):4842-4848.
-
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci Adv. 2023 03 29; 9(13):eade8778.
-
Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG Oncology. J Surg Oncol. 2023 Apr; 127(5):871-881.
-
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR?+?/HER2?-) advanced/metastatic breast cancer. Breast Cancer Res Treat. 2023 Jan; 197(2):319-331.
-
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789.
-
Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem. 2022 08; 298(8):102226.
-
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022 07; 607(7917):119-127.
-
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
-
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol. 2021; 97(8):1121-1128.